ZAP-70, CD38 and IGHV mutations have all been reported to have prognostic impact in chronic lymphocytic leukemia (CLL), both individually and in paired combinations. We aimed to determine whether the combination of all three factors provided more refined prognostic information concerning the treatment-free interval (TFI) from diagnosis. ZAP-70, CD38 and IGHV mutations were evaluated in 142 patients. Combining all three factors, the ZAP-70-/CD38-/Mutated group showed the longest median TFI (62 months, n = 37), ZAP-70+/CD38+/Unmutated cases the shortest (11 months, n = 37) and cases discordant for > or = 1 factor, an intermediate TFI (27 months, n = 68) (p = 0.006). Analysis of discordant cases revealed values that were otherwise masked when measuring single prognostic factors. The presence or absence of cytogenetic abnormalities did not explain the variability among discordant cases. Simultaneous analysis of ZAP-70, CD38 and IGHV mutations in CLL provides more discriminatory prediction of TFI than any factor alone.

Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL / Alison, Morilla; David Gonzalez De, Castro; DEL GIUDICE, Ilaria; Nnenna, Osuji; Monica, Else; Ricardo, Morilla; Vasantha Brito, Babapulle; Hannah, Rudenko; Estella, Matutes; Claire, Dearden; Daniel, Catovsky; Gareth J., Morgan. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 49:11(2008), pp. 2108-2115. [10.1080/10428190802360810]

Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL

DEL GIUDICE, ILARIA;
2008

Abstract

ZAP-70, CD38 and IGHV mutations have all been reported to have prognostic impact in chronic lymphocytic leukemia (CLL), both individually and in paired combinations. We aimed to determine whether the combination of all three factors provided more refined prognostic information concerning the treatment-free interval (TFI) from diagnosis. ZAP-70, CD38 and IGHV mutations were evaluated in 142 patients. Combining all three factors, the ZAP-70-/CD38-/Mutated group showed the longest median TFI (62 months, n = 37), ZAP-70+/CD38+/Unmutated cases the shortest (11 months, n = 37) and cases discordant for > or = 1 factor, an intermediate TFI (27 months, n = 68) (p = 0.006). Analysis of discordant cases revealed values that were otherwise masked when measuring single prognostic factors. The presence or absence of cytogenetic abnormalities did not explain the variability among discordant cases. Simultaneous analysis of ZAP-70, CD38 and IGHV mutations in CLL provides more discriminatory prediction of TFI than any factor alone.
2008
cd38; cll; ighv mutations; treatment-free interval; zap-70
01 Pubblicazione su rivista::01a Articolo in rivista
Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL / Alison, Morilla; David Gonzalez De, Castro; DEL GIUDICE, Ilaria; Nnenna, Osuji; Monica, Else; Ricardo, Morilla; Vasantha Brito, Babapulle; Hannah, Rudenko; Estella, Matutes; Claire, Dearden; Daniel, Catovsky; Gareth J., Morgan. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - STAMPA. - 49:11(2008), pp. 2108-2115. [10.1080/10428190802360810]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/481320
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 35
social impact